[ biotech news ] Bridge Pharmaceuticals Dedicates Its Preclinical Drug Development Laboratory in

Bridge Pharmaceuticals Dedicates Its Preclinical Drug Development
Laboratory in Beijing

Bridge Pharmaceuticals Inc., Together With WI Harper and Vital
Bridge, Announce the Dedication of Its State-of-the-Art Preclinical
Drug Development Laboratory at Zhongguancun Life Science Park in
Beijing

Today, Bridge Pharmaceuticals had the dedication ceremony for its
recently completed Bridge Zhongguancun Preclinical Drug Development
Laboratory I. In attendance at the ceremony were: San Francisco
Mayor Gavin Newsom; Deputy Mayor Beijing Municipal Office Hao Lu;
Beijing Deputy Mayor Bo-Yuan Fan; US Embassy Senior Commercial
Officer Craig Allen; Former Beijing Deputy Mayor Zhao-Guang Hu;
Director of Beijing Municipal Industrial Development Bureau Lian-
Yuan Cheng; Director of Beijing Municipal Science Technology Office
Hai Feng; and Former San Francisco Mayor Frank Jordon.

This 7,800 square meter facility puts Bridge at the forefront of
preclinical outsourcing to China and will be the first and only US
level GLP and AAALAC designed facility in China. The Zhongguancun
facility will house primates, rodents, canines, rabbits. Services
will include: FDA compliant GLP toxicology, pharmacology, predictive
PK/ADMET, safety pharmacology, formulation and other services.
Through its Vital Bridge joint venture, Bridge has expert local
partners in China that provide animal supplies from the largest and
only US-franchised (Charles River and Marshall Farms) quality animal
breeding facilities in China.

For Bridge, the opening of this facility marks the next phase in
outsourcing preclinical drug development to Asia. By controlling its
own facility in China, Bridge will have the capacity and expertise
to provide FDA compliant preclinical drug development services to
pharmaceutical and biotech companies throughout the world. This new
facility positions Bridge as the leading preclinical CRO in China
targeting US and EU biopharmaceutical companies.

"The San Francisco Bay Area is the birthplace of biotech and has
remained the worldwide leader in life sciences innovation.
Escalation of the price of drugs, as evidenced by California's
recent ballot initiative, is an increasing hardship and concern,"
said San Francisco Mayor Gavin Newsom. "By combining the technical
resources and innovation of both the San Francisco Bay Area and
Beijing's life sciences community, this state-of-the-art facility
represents the next wave of global cooperation and evolution of life
sciences development. Bridge, and companies like Bridge, will allow
San Francisco to remain competitive in the life sciences, and cost
effectively develop more drugs, for smaller markets, in the new era
of personalized molecular medicine. We are pleased to see that a Bay
Area company, Bridge Pharmaceuticals, is taking the lead in this
exciting global evolution of the very best of the east and west."

Founded in 2004, Bridge Pharmaceuticals, Inc. was spun-out of SRI
International (formerly Stanford Research Institute) to develop
preclinical service and drug development capabilities through
leverage of the Asian market. To date, Bridge has been
subcontracting work through laboratories in China and Taiwan
(Beijing, Shanghai, Chengdu, Taipei and elsewhere). Bridge is the
first company to successfully use all China preclinical and CMC data
for successful filing of IND's with the US FDA and did so twice this
year.

"Two years ago, we asked a simple question -- why can't one perform
FDA compliant drug development in China for US clients at a fraction
of the normal price?" CEO and President, Glenn Rice, Ph.D.
said. "China has the world's leading primate animal supply, highly
qualified technical staff, good English language skills and
excellent worker productivity, in addition to significant cost
savings. Bridge builds on China's strengths by adding: SOP sourcing
from the US, world class facilities in the leading life sciences
park in China, FDA compliance, AAALAC level animal welfare, real
time data monitoring, combined with a US headquartered company that
envisions flexible partnerships.

"Of course doing business in China takes a lot of local know how,
experienced investment strategy and government support. We are
combining the best of east and west and we are confident it is going
to revolutionize preclinical drug development worldwide. We are
indebted to our investors, particularly Peter Liu, Chairman of the
WI Harper Group who has guided our business from day one in China."

About Bridge Pharmaceuticals

Bridge Pharmaceuticals is a US-headquartered, SRI International spin-
off company focused on providing cost effective, FDA compliant drug
development services in Asia for US, EU and Asian based clients.
Bridge has also formed BridgeNet, an unprecedented network of pre-
screened chemical and manufacturing service providers in China and
Taiwan, which provides western clients with a single point of
contact to access highly qualified and cost effective drug
development services in Asia. Bridge provides complete end-to-end
drug development expertise including US IND submissions. Bridge
focuses its development work in Taiwan and China. For more
information, visit www.BridgePharmaceuticals.com or call 650-859-
3853.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Scientists Allege U.S. Losing Lead in Stem Cell Research; Advanced Cell Technolo
Scientists Allege U.S. Losing Lead in Stem Cell Research; Advanced
Cell Technology Generated Stem Cell Embryos in 2003, but Lack of
Federal Funding Hampered Progress

Figure Cloned Human Morula : A human embryo generated by SCNT at
Advanced Cell Technology in 2003 (Photo: Business Wire).

Nov. 23, 2005--South Korea's World Stem Cell Hub could become the
leading center for stem cell and therapeutic cloning research,
because of the chilling effect U.S. policy has had on stem cell
research, according to Dr. Robert Lanza, Vice President for Medical
& Scientific Development of Advanced Cell Technology, Inc. (OTCBB:
ACTC), and Professor Ronald Green, Director of Dartmouth's Ethics
Institute and chair of Advanced Cell Technology's Ethics Advisory
Board, writing in the November 24th issue of the scientific journal
Nature. "It reflects how far the United States has fallen behind its
competitors in this pivotal area and how much the lack of federal
leadership has handicapped US efforts," allege Lanza and Green.

The current administration's restrictive policy also impacted
Advanced Cell Technology's own promising program to produce human
embryos through somatic cell nuclear transfer (SCNT), Lanza and
Green state. "We believe the South Koreans are winning the race,
because "in our view (the current administration's) restrictive
policy on funding stem cell research was a major factor." They add,
that the Administration "repeatedly spoke out in support of
legislation in Congress that would ban all therapeutic cloning
research."

Advanced Cell Technology's own human SCNT program was initiated in
2000, with strong ethical guidelines provided by the company's
Ethics Advisory Board to assist researchers in this pioneering egg
donor program.

"Apart from the egos involved here," said Green, "the stakes for
this research are important. Although the South Korean team deserves
every credit for their accomplishments, the current absence of a
strong U.S. competitor in this research narrows the range of
directions likely to be explored."

"By driving research out of this country, (U.S. government) policies
have also made it difficult to develop and apply rigorous ethical
oversight for this research," Green added.

After Advanced Cell Technology scientists created the first early (4-
6 cell stage) cloned human embryos in 2001, they were able to
quickly generate more advanced stem-cell-competent stage embryos. In
the last SCNT experiments in 2003, the company had 16 eggs, of which
13 (81%) developed into healthy-looking 8-16 cell morula, which have
the capacity to generate stem cells in both animals and humans.

Advanced Cell Technology carried out control experiments involving
just activation. Although healthy looking in appearance, both the
SCNT embryos and parthenote controls failed to develop into
blastocysts, because the wrong culture media were being used. When
the company's scientists changed the media and repeated the
parthenote controls the next time, 12 of 14 (86%) 8-16 cell stage
morula went on to develop into blastocysts.

"As early as 2002 and 2003," Lanza said, "the Advanced Cell
Technology research team had the science worked out and simply
needed to repeat the experiment using the right media in order to
obtain stem cells. Unfortunately, these were the last SCNT
experiments performed in the Unite States."

Lanza and Green conclude by noting that the company was not a
special case. "Indeed, the stem-cell area as a whole has continued
to encounter difficulties in garnering sufficient financial
support."

About Advanced Cell Technology

Advanced Cell Technology, Inc. is a biotechnology company applying
stem cell technology in the emerging field of regenerative medicine.
The company is currently headquartered in Worcester, Massachusetts.
For more information about the company visit
http://www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and
operating results, future growth in research and development
programs, potential applications of our technology, opportunities
for the and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements
that are not statements of historical fact (including statements
containing the
words "will," "believes," "plans," "anticipates," "expects," "estimat
es," and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, including:
limited operating history, need for future capital, risks inherent
in the development and commercialization of potential products,
protection of our intellectual property, and economic conditions
generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in the company's periodic reports, including the
report on Form 10-QSB for the quarter ended September 30, 2005.

Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its forward-
looking statements if those beliefs, opinions, expectations, or
other circumstances should change.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TGen and Morehouse School of Medicine Sign Collaborative Agreement

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

TGen and Morehouse School of Medicine Sign Collaborative Agreement

10-31-2005

MEDIA ADVISORY
TGen and Morehouse School of Medicine Sign Collaborative Agreement

Media Contact:
Amy Erickson
TGen
602.343.8522
aerickson@tgen.org

Monday, November 21

The Translational Genomics Research Institute (TGen) and the
Morehouse School of Medicine (MSM), located in Atlanta, GA, are
entering into a research collaboration to conduct joint projects in
Bioinformatics, Diabetes, Neurogenomics, Cancer, and Cardiovascular
Disease. The collaboration leverages the strengths of both
institutions to accomplish their translational research missions.

On Monday, November 21st, Dr. David Satcher, former Surgeon General
of the United States and current Interim President and Director for
the Morehouse School of Medicine will be at TGen to sign the
collaborative agreement.

The TGen-MSM partnership furthers the school's potential to emerge
as a preeminent minority organization in translational genomics
research and allows TGen to make a positive impact in creating
earlier diagnostic tools and treatments for disease.

Following the signing ceremony, Dr. Satcher will give a lecture on
health disparities at Phoenix College.

Where: TGen Headquarters, Board Room, 445 N. Fifth Street, Phoenix

When: November 21, 2005
8:45-9:15a.m.—Media set-up
9:15-9:45a.m.—Signing ceremony

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] AlphaVax Named the Triangle's Fastest Growing Private Biotech Company

AlphaVax Named the Triangle's Fastest Growing Private Biotech
Company


RESEARCH TRIANGLE PARK, N.C., Nov. 11
For the third consecutive year, AlphaVax, a North Carolina-based
vaccine company, has been recognized as one of Research Triangle
Park's fastest growing private companies by Triangle Business
Journal's Fast 50 Awards program. At this year's awards ceremony
held on November 3rd at Raleigh's North Ridge Country club, AlphaVax
was honored as the 10th fastest growing private company overall
and was the top ranked biotechnology company. The Company ranked as
the 49th and 27th fastest growing company on the Fast 50 list in
2003 and 2004, respectively.

Commenting on the award, Peter Young, President and CEO of
AlphaVax, said,
"We are extremely gratified by this award. Considering that all our
products
are still in development, and that this achievement is not based on
product
sales but the strength of our technology and our organizational
expertise, we
think our performance is pretty competitive."
The rankings of the Triangle's Fast 50 were determined by
PricewaterhouseCoopers LLP who evaluated revenues and percentage
growth of
locally headquartered private companies. This year, AlphaVax
received $10
million in new grant awards from the National Institutes of Health
for
pandemic influenza and smallpox vaccine development, bringing their
cumulative
total to over $75 million in grant and foundation funding.
Substantial annual
revenue growth, from $4.5 million in 2001 to a projected $16.5
million in
2005, has enabled the Company to expand its product pipeline to 12
vaccine
development programs using its proprietary vaccine platform
technology.
AlphaVax has grant supported vaccine development projects in HIV,
biodefense, influenza and SARS and is working with a number of
academic and
industry partners on vaccines for important diseases like herpes and
human
papilloma virus (the principal cause of cervical cancer), as well as
vaccines
that can be used to treat different types of cancer. The Company is
located
in Research Triangle Park and currently employs 70 people. It also
manages a
GMP manufacturing operation in a leased vaccine production facility
in Lenoir,
North Carolina.
All 50 winning companies are profiled in an in-depth special
Fast 50
Awards section in Triangle Business Journal's November 4 edition.

SOURCE AlphaVax

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
UCR News: Biotech Entrepreneur is Keynote Speaker at Regional Undergraduate Research Conference Hosted by UC Riverside
Biotech Entrepreneur is Keynote Speaker at Regional Undergraduate Research Conference Hosted by UC Riverside
Tina Nova will address the Southern California Conference on Undergraduate Research
(November 11, 2005)


Tina Nova
--------------------------------------------------------------------------------

RIVERSIDE, Calif. – www.ucr.edu – Biotechnology executive and entrepreneur Tina Nova, a 1982 Ph.D. recipient of the University of California, Riverside, will give the keynote address at the 13th Annual Southern California Conference on Undergraduate Research, scheduled for Saturday, Nov. 19 at UCR. The public is invited but must register for the event. To register, visit the conference Web site.

Nova is the chief executive officer of Genoptix, Inc., the fourth biotechnology firm she has co-founded in the San Diego area. She will address more than 600 students plus their faculty mentors gathered at the largest SCCUR conference so far, according to conference organizer Chris Foster, director of undergraduate research at the Bourns College of Engineering at UCR.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Funding Round for Cambridge Biotech Company Completed

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Funding Round for Cambridge Biotech Company Completed

Cambridge-based biotech company, Activotec, has just completed a
significant funding round to enable it to accelerate the growth of
the company.

Cambridge-based biotech company, Activotec, has just completed a
significant funding round to enable it to accelerate the growth of
the company.

Activotec, which has its trading base in Cambridge UK and an R&D and
production facility in Southampton, was founded in 2002 as a spin
out from the University of Southampton. The Company modifies
peptides and proteins to make them therapeutically useful and
already has a solid customer base for its products.

The money was raised quickly through a syndicate mainly composed of
private high net worth investors, was significantly oversubscribed
and had to be scaled back.

Activotec chief executive, Chris Littlewood, commented: "The funds
will be invested in further research and development while expanding
our current business. This will assist us in our dual strategy of
creating and licensing technology to drug developers while also
quickly growing our custom peptide and synthesiser sales.

About Activotec
Activotec develops novel methods for the synthesis of peptides and
proteins and provides innovative custom synthesis services,
instrumentation and chemicals for chemical research and development.

Its mission is to establish Activotec as the partner of choice for
peptide-based drug discovery.

If you would like more information please call them on +44 (0)1223
260008.

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Molecular Profiling Institute, IBM partner on genomics project: Financial News - Yahoo! Finance
Molecular Profiling Institute, IBM partner on genomics project: Financial News - Yahoo! Finance


Molecular Profiling Institute, IBM partner on genomics project
Tuesday November 8, 12:35 am ET


The Molecular Profiling Institute Inc. in Phoenix is another step closer to generating tools to help physicians personalize medicine for patients.
The Phoenix company is working with IBM (NYSE: IBM - News) on a Healthcare Life Sciences Collaboration Project to create a Personalized Medicine Expert System. This proprietary system allows physicians the ability to apply genomic advances to the practice of medicine.

ADVERTISEMENT


"The goal of the Molecular Profiling Institute is to give physicians the tools they need to provide a greater level of personalized medicine in the treatment of their patients," said Dr. Robert J. Penny, president and chief executive of Molecular Profiling. "Our alliance with IBM should allow Molecular Profiling to offer physicians a tailored medical strategy for their individual patients."

At this stage of the development, Molecular Profiling provides clinical data, modeling, and system testing. The company also is designing and building a clinical information management system and genomic analytic software, along with synonym and taxonomy dictionaries.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech